Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer

Liu, Bo; Liang, Han; Liu, Junyan; Han, Sileny; Chen, Zhe; Jiang, Lixi

doi:10.2147/ijn.s115136

Cited by 103 publications

(48 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, combinations of chemotherapeutic drugs are widely used for various cancer types (Liu et al, ; Zhang et al, ). Importantly, the advantage of using multiple drugs are seen as the lowering of doses which could lead to lower resistance and the retention of the same efficacy or sometimes a higher efficacy, a synergistic effect (Glasgow & Chougule, ; He et al, ; Liboiron & Mayer, ).…”

Section: Introductionmentioning

confidence: 99%

Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence

Lin

Hsu

Tsai

et al. 2019

British J Pharmacology

286

175

View full text Add to dashboard Cite

Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and amelioration of adverse effects that has been broadly applied to various cancer types. Additionally, seeking natural‐based alternatives with less toxicity has become more important. Experimental evidence suggests that herbal extracts such as Solanum nigrum and Claviceps purpurea and isolated herbal compounds (e.g., curcumin, resveratrol, and matairesinol) combined with antitumoral drugs have the potential to attenuate resistance against cancer therapy and to exert chemoprotective actions. Plant products are not free of risks: Herb adverse effects, including herb–drug interactions, should be carefully considered. Linked Articles This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc

show abstract

Section: Introductionmentioning

confidence: 99%

Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence

Lin

Hsu

Tsai

et al. 2019

British J Pharmacology

286

175

View full text Add to dashboard Cite

show abstract

“…The drug-loading (DL) was determined as the weight ratio (W) of the loaded drug to the drugloaded SLNs. The entrapment efficacy (EE) of both SLNs was determined from the weight (W) ratio between the drug incorporated in SLNs and the initial drug fed into the formulation 10 .…”

Section: Determination Of Drug Entrapment Efficiencymentioning

confidence: 99%

Untitled

2020

IJPSR

View full text Add to dashboard Cite

The objective of the present study is to develop, evaluate and compare potent phytoconstituents of curcumin loaded solid lipid nanoparticles (CUR-SLN) and Paclitaxel loaded solid lipid nanoparticles (PTX-SLN) for the treatment of malignancy. Curcumin is an active phenolic compound of Curcuma longa as a promising phytoconstituent has been extensively studied over the past several years. The result of these studies has indicated that the curcumin (CUR) acts on multiple molecular targets to selectively kill tumor cells with low intrinsic toxicity. The well-known anticancer agent Paclitaxel (PTX) is used for its effectiveness in the treatment of a wide range of tumors cells. However, due to the hydrophobic nature of PTX limits its effective application as anticancer drug. This study utilizes the immense potential of nanotechnology, particularly SLNs, in improving safety & bioavailability of CUR and PTX. SLN was chosen due to their excellent lipoidal drug carrier properties, physiological compatibility, and economic standpoint. In this study physical mixture of CUR-SLN and PTX-SLN formulation and PTX-SLN formulation were examined on Ehrlich ascites carcinoma (EAC) cells for anticancer study. It was observed that the physical mixture of CUR-PTX and PTX-SLN was more effective than PTX-SLN.A great deal of attention has been paid to delivery systems based on highly biocompatible and biodegradable components such as lipids and phospholipids. As a result, different types of nanocarriers such as SLN and nanostructured lipid carriers (NLC) have been developed 4 . SLN and NLC were designed as exceptionally safe colloidal carriers for the delivery of poorly soluble drugs. SLN/NLC has the particularity of being composed of excipients already approved for use in medicines for human use, which offers a great advantage over any other nanoparticulate system developed from novel materials 5 . SLNs were reported as an alternative drug delivery system to traditional polymeric nanoparticles. SLN for controlled release drug delivery-drug release and release mechanism.

show abstract

“…Other study, NPs were developed. (TOS-CDDP) (TAT-PTX/TOS-CDDP SLNs) with co-administration of paclitaxel (PTX) and α-tocopherol succinate-cisplatin prodrug (TOS-CDDP) -cisplatin prodrug objective of achieving synergistic tumor activity against cervical cancer, achieving satisfactory results of internalization in HeLa cells and showing a synergistic effect on suppression of cervical tumor cell growth with high tumor tissue accumulation, superior antitumor efficiency and low in vivo toxicity [79].…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

“…PNPs are particle with size range of 1-100 nm [141,142] with numerous advantages, as protection against enzymatic degradation, controlled release and high penetration capacity [143]. Into PNPs is possible loading molecules, as antibodies, DNA, RNA, and its allow a specific interaction in the specific targets, as cancer cells [79,144,145]. However, there are some disadvantages as the degradation (e.g.…”

Section: Polymeric Nanoparticles (Pnps)mentioning

confidence: 99%

Highlights in nanocarriers for the treatment against cervical cancer

Medina-Alarcón

Voltan

Fonseca-Santos

et al. 2017

Materials Science and Engineering: C

View full text Add to dashboard Cite

Cervical cancer is the second most common malignant tumor in women worldwide and has a high mortality rate, especially when it is associated with human papillomavirus (HPV). In US, an estimated 12,820 cases of invasive cervical cancer and an estimated 4210 deaths from this cancer will occur in 2017. With rare and very aggressive conventional treatments, one sees in the real need of new alternatives of therapy as the delivery of chemotherapeutic agents by nanocarriers using nanotechnology. This review covers different drug delivery systems applied in the treatment of cervical cancer, such as solid lipid nanoparticles (SNLs), liposomes, nanoemulsions and polymeric nanoparticles (PNPs). The main advantages of drug delivery thus improving pharmacological activity, improving solubility, bioavailability to bioavailability reducing toxicity in the target tissue by targeting of ligands, thus facilitating new innovative therapeutic technologies in a too much needed area. Among the main disadvantage is the still high cost of production of these nanocarriers. Therefore, the aim this paper is review the nanotechnology based drug delivery systems in the treatment of cervical cancer.

show abstract

Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer

Cited by 103 publications

References 55 publications

Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence

Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence

Untitled

Highlights in nanocarriers for the treatment against cervical cancer

Contact Info

Product

Resources

About